X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6) 6
humans (5) 5
female (4) 4
analysis (3) 3
male (3) 3
medicine, general & internal (3) 3
abridged index medicus (2) 2
acute coronary syndrome (2) 2
acute coronary syndromes (2) 2
adult (2) 2
aged (2) 2
angina (2) 2
animals (2) 2
cancer (2) 2
cardiovascular diseases (2) 2
cardiovascular diseases - mortality (2) 2
care and treatment (2) 2
cerebral infarction (2) 2
differential cross sections (2) 2
double-blind method (2) 2
down-regulation (2) 2
engineering, chemical (2) 2
gene-expression (2) 2
hematology (2) 2
megakaryocytes (2) 2
mev range 100-1000 (2) 2
middle aged (2) 2
myeloid differentiation (2) 2
myocardial infarction (2) 2
myocardial-infarction (2) 2
nfatc transcription factors - genetics (2) 2
nfatc transcription factors - metabolism (2) 2
piperidines - therapeutic use (2) 2
scattering amplitudes (2) 2
stroke (2) 2
studies (2) 2
1,3-propanediol-butanol-ethanol fermentation (1) 1
abe fermentation (1) 1
abuse (1) 1
accountability (1) 1
acetic acid (1) 1
acetic-acid (1) 1
acetobutylicum (1) 1
acetone (1) 1
activated-t-cells (1) 1
acute coronary syndrome - drug therapy (1) 1
acute coronary syndrome; aged; anticholesteremic agents; azetidines; cardiovascular diseases; cholesterol, ldl; double-blind method; drug therapy, combination; ezetimibe; female; humans; hydroxymethylglutaryl-coa reductase inhibitors; kaplan-meier estimate; male; middle aged; simvastatin; triglycerides; medicine (all (1) 1
adolescent (1) 1
adsorption-isotherms (1) 1
africa (1) 1
aging - genetics (1) 1
aging - metabolism (1) 1
aging - pathology (1) 1
alumina (1) 1
anemia (1) 1
anemia - genetics (1) 1
anemia - metabolism (1) 1
anemia - pathology (1) 1
angina pectoris (1) 1
angina, unstable - complications (1) 1
angina, unstable - drug therapy (1) 1
angular distribution (1) 1
anticholesteremic agents (1) 1
anticholesteremic agents - adverse effects (1) 1
anticholesteremic agents - therapeutic use (1) 1
apoptosis (1) 1
apoptosis - drug effects (1) 1
apoptosis - genetics (1) 1
atorvastatin (1) 1
ausgangsmaterial (1) 1
azetidines (1) 1
azetidines - adverse effects (1) 1
azetidines - therapeutic use (1) 1
battered women - statistics & numerical data (1) 1
betriebsbedingung (1) 1
bioconversion (1) 1
biofuel (1) 1
biofuels (1) 1
biokonversion (1) 1
biokraftstoff (1) 1
birth (1) 1
bone marrow (1) 1
bone marrow - metabolism (1) 1
bone marrow - pathology (1) 1
bone-marrow-transplantation (1) 1
brain - drug effects (1) 1
brief psychiatric rating scale (1) 1
butanol (1) 1
calcineurin (1) 1
calcineurin - metabolism (1) 1
calcineurin inhibitors (1) 1
calcinosis - genetics (1) 1
calcinosis - metabolism (1) 1
calcinosis - pathology (1) 1
calcium ionophores - pharmacology (1) 1
carbon 12- proton reactions (1) 1
cardiac outcomes (1) 1
cardiology and cardiovascular system (1) 1
cardiovascular disease (1) 1
cardiovascular diseases - epidemiology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Liver | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
by Leung, Wilson and Shaffer, Christopher D and Reed, Laura K and Smith, Sheryl T and Barshop, William and Dirkes, William and Dothager, Matthew and Lee, Paul and Wong, Jeannette and Xiong, David and Yuan, Han and Bedard, James E.J and Machone, Joshua F and Patterson, Seantay D and Price, Amber L and Turner, Bryce A and Robic, Srebrenka and Luippold, Erin K and McCartha, Shannon R and Walji, Tezin A and Walker, Chelsea A and Saville, Kenneth and Abrams, Marita K and Armstrong, Andrew R and Armstrong, William and Bailey, Robert J and Barberi, Chelsea R and Beck, Lauren R and Blaker, Amanda L and Blunden, Christopher E and Brand, Jordan P and Brock, Ethan J and Brooks, Dana W and Brown, Marie and Butzler, Sarah C and Clark, Eric M and Clark, Nicole B and Collins, Ashley A and Cotteleer, Rebecca J and Cullimore, Peterson R and Dawson, Seth G and Docking, Carter T and Dorsett, Sasha L and Dougherty, Grace A and Downey, Kaitlyn A and Drake, Andrew P and Earl, Erica K and Floyd, Trevor G and Forsyth, Joshua D and Foust, Jonathan D and Franchi, Spencer L and Geary, James F and Hanson, Cynthia K and Harding, Taylor S and Harris, Cameron B and Heckman, Jonathan M and Holderness, Heather L and Howey, Nicole A and Jacobs, Dontae A and Jewell, Elizabeth S and Kaisler, Maria and Karaska, Elizabeth A and Kehoe, James L and Koaches, Hannah C and Koehler, Jessica and Koenig, Dana and Kujawski, Alexander J and Kus, Jordan E and Lammers, Jennifer A and Leads, Rachel R and Leatherman, Emily C and Lippert, Rachel N and Messenger, Gregory S and Morrow, Adam T and NewcombVictoria, Haley J and Plasman, Plasman and Potocny, Stephanie J and Powers, Michelle K and Reem, Rachel M and Rennhack, Jonathan P and Reynolds, Katherine R and Reynolds, Lyndsey A and Rhee, Dong K and Rivard, Allyson B and Ronk, Adam J and Rooney, Meghan B and Rubin, Lainey S and Salbert, Luke R and Saluja, Rasleen K and Schauder, Taylor and Schneiter, Allison R and Schulz, Robert W and Smith, Karl E and Spencer, Sarah and Swanson, Bryant R and Tache, Melissa A and Tewilliager, Ashley A and Tilot, Amanda K and VanEck, Eve and Villerot, Matthew M and ... and Participating Students Fac Genomic
G3: Genes, Genomes, Genetics, ISSN 2160-1836, 2015, Volume 5, Issue 5, pp. 719 - 740
Journal Article
by Leung, Wilson and Shaffer, Christopher D and Reed, Laura K and Smith, Sheryl T and Barshop, William and Dirkes, William and Dothager, Matthew and Lee, Paul and Wong, Jeannette and Xiong, David and Yuan, Han and Bedard, James E. J and Machone, Joshua F and Patterson, Seantay D and Price, Amber L and Turner, Bryce A and Robic, Srebrenka and Luippold, Erin K and McCartha, Shannon R and Walji, Tezin A and Walker, Chelsea A and Saville, Kenneth and Abrams, Marita K and Armstrong, Andrew R and Armstrong, William and Bailey, Robert J and Barberi, Chelsea R and Beck, Lauren R and Blaker, Amanda L and Blunden, Christopher E and Brand, Jordan P and Brock, Ethan J and Brooks, Dana W and Brown, Marie and Butzler, Sarah C and Clark, Eric M and Clark, Nicole B and Collins, Ashley A and Cotteleer, Rebecca J and Cullimore, Peterson R and Dawson, Seth G and Docking, Carter T and Dorsett, Sasha L and Dougherty, Grace A and Downey, Kaitlyn A and Drake, Andrew P and Earl, Erica K and Floyd, Trevor G and Forsyth, Joshua D and Foust, Jonathan D and Franchi, Spencer L and Geary, James F and Hanson, Cynthia K and Harding, Taylor S and Harris, Cameron B and Heckman, Jonathan M and Holderness, Heather L and Howey, Nicole A and Jacobs, Dontae A and Jewell, Elizabeth S and Kaisler, Maria and Karaska, Elizabeth A and Kehoe, James L and Koaches, Hannah C and Koehler, Jessica and Koenig, Dana and Kujawski, Alexander J and Kus, Jordan E and Lammers, Jennifer A and Leads, Rachel R and Leatherman, Emily C and Lippert, Rachel N and Messenger, Gregory S and Morrow, Adam T and Newcomb, Victoria and Plasman, Haley J and Potocny, Stephanie J and Powers, Michelle K and Reem, Rachel M and Rennhack, Jonathan P and Reynolds, Katherine R and Reynolds, Lyndsey A and Rhee, Dong K and Rivard, Allyson B and Ronk, Adam J and Rooney, Meghan B and Rubin, Lainey S and Salbert, Luke R and Saluja, Rasleen K and Schauder, Taylor and Schneiter, Allison R and Schulz, Robert W and Smith, Karl E and Spencer, Sarah and Swanson, Bryant R and Tache, Melissa A and Tewilliager, Ashley A and Tilot, Amanda K and VanEck, Eve and Villerot, Matthew M and ...
G3: Genes|Genomes|Genetics, ISSN 2160-1836, 05/2015, Volume 5, Issue 5, pp. 719 - 740
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | CARDIOVASCULAR SAFETY | MELLITUS | OUTCOMES | MYOCARDIAL-INFARCTION | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer
Journal Article